Ab#4512 ASCO #ASCO24 by #SahilDoshi 👉tinyurl.com/448t2yym 👉Analysis of outcomes w/ 1L systemic Rx in chromophobe mRCC #kidneycancer 👉 targeted doublet regimens ⬆️ TTF and OS compared to monotherapies 👇Martin Voss OncoAlert UroToday.com Kidney Cancer KidneyCAN

Ab#5001 ASCO #ASCO24 by #MSmith 👉tinyurl.com/mtfzzmt9 👉In Ph3 CYCLONE 2 trial in mCRPC #Prostatecancer 👉 Abemaciclib + abi vs abi did not improve outcomes, questioning the role of CDK4/6 inhibition👇Rana McKay Arun Azad GU Cancer Research Program @HuntsmanCancer OncoAlert UroToday.com Uromigos

Insightful work from Bilal A. Siddiqui, MD Sumit Subudhi Padmanee (Pam) Sharma, MD, PhD and team! A mechanistic understanding of irAEs will lead to significant advances for our patients Nazli Dizman Sumanta K. Pal, MD, FASCO

Congrats to Ana Aparicio and team on this trial of 192 men with mCRPC - Andy Hahn
Clinical Cancer Research Neeraj Agarwal, MD, FASCO Padmanee (Pam) Sharma, MD, PhD Sumit Subudhi Bilal A. Siddiqui, MD Tian Zhang, MD, MHS Misha Beltran PCF Science Brian F. Chapin Nazli Dizman
oncodaily.com/64302.html

#Cancer #OncoDaily #Oncology

Just in European Urology Oncology: We present gene expression in denovo vs relapsed (metachronous) mHSPC #ProstateCancer 👉⬆️ inflammatory pathways in denovo vs. ⬆️ AR pathways in relapsed mHSPC Thanks to mentors Umang Swami Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer OncoAlert Link bit.ly/3UTX3nn

Andy Hahn Ana Aparicio Clinical Cancer Research Padmanee (Pam) Sharma, MD, PhD Sumit Subudhi Bilal A. Siddiqui, MD Tian Zhang, MD, MHS Misha Beltran PCF Science Brian F. Chapin MD Anderson Cancer Center Nazli Dizman Congrats Ana Aparicio and the team, for this innovative IIT study and the crucial translational data in the @ccr_aacr A lot to learn from your team MD Anderson Cancer Center PCF Science UroToday.com Misha Beltran Howard Soule Nick James Nima Sharifi Andy Hahn

A treat to hear from the engaging and thoughtful Andy Hahn on his approach to treating patients with localized prostate cancer! MD Anderson Cancer Center

#AUA24 Amer. Urol. Assn. plenary session👉We discussed critical role of the PSMA PET scan in management of #ProstateCancer with biochemical recurrence (BCR), Current Rx with salvage RT, results of Embark & ongoing ARASTEP trial in PSMA-PET+BCR👇Stacy Loeb, MD OncoAlert UroToday.com

🔥 📰 Hot of the press: sharing our work on HRR testing for prostate cancer using US database. Most mCRPC still don't get HRR testing. +pts being tested earlier. Race, age, insurance, low socioecon st, outside academia⏩ low testing Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Rana McKay 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

Excited to publish Harvard Data Science Review an overview on interpreting randomized controlled trials focusing on information. By prioritizing this fundamental principle, previously obscure statistical concepts reveal their intrinsic beauty: hdsr.mitpress.mit.edu/pub/yb9eq8ja/r…

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉Excellent talk by Heather H. Cheng on who should undergo germ line testing?👉ongoing neoadjuvant trials in germline mutation+ #prostatecancer and take home message👇OncoAlert PCF Science silke gillessen

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉Ana Aparicio ‘s excellent perspective on how to interpret clinical genomic tests👇 and framework for drug development in advanced #prostatecancer & highlights ongoing SWOG Cancer Research Network 2312 trial OncoAlert PCF Science

thankful to Sara Taveras Alam, MD for letting me share this exciting, expansive study on racial disparities in MDS inpatient mortality outcomes at Binaytara Foundation #SCHD24 and Martha Mims for sharing this opportunity w me

Just in BMC 👉Full protocol of our recently initiated, National Cancer Institute RO1 funded, randomized trial of creatine supplementation + Resistance training in advanced #ProstateCancer undergoing ADT Adriana M Coletta, PhD, MS, RD Neli Ulrich, PhD OncoAlert PCF Science Huntsman Cancer Institute UroToday.com

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

Tian Zhang, MD, MHS Brian F. Chapin CPRIT MD Anderson Cancer Center Tudor Borza Michigan Urology Matt Campbell MD, MS Dr. Andy Wang 🇺🇦 Todd 〽️ Morgan, MD Surena F Matin MD Andy Hahn Excellent talk on step wise approach to implementation science within MUSIC by Tudor Borza I think we can take back very tangibly to our collaborations